Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2021 - 03 - 02 save search
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
Published: 2021-03-02 (Crawled : 21:04) - globenewswire.com
SRNE | $0.02 33.33% -8.85% 97K
|
Health Technology
|
| O: 1.37%
H: 2.41%
C: -5.21%
covid fda clearance treatment fda phase 1 drop positive phase 3 phase 2 clearance
FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation
Published: 2021-02-25 (Crawled : 16:36) - fda.gov
SRPT | $124.25 6.09% 5.75% 1.5M
|
Health Technology
|
| O: 0.73%
H: 2.11%
C: 1.39%
fda treatment duchenne approval fda approval rare
Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies
Published: 2021-03-02 (Crawled : 14:04) - globenewswire.com
SRNE | $0.02 33.33% -8.85% 97K
|
Health Technology
|
| O: 3.71%
H: 1.22%
C: -11.19%
fda clearance treatment fda antibody trial anti-cd40 clearance
Eyenovia Announces FDA Acceptance of the MydCombi NDA
Published: 2021-03-02 (Crawled : 13:00) - biospace.com/
EYEN | $0.5835 7.54% 7.99% 770K
|
Health Technology
|
| O: 10.74%
H: 4.53%
C: -5.61%
fda fda acceptance eye mydcombi
G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
Published: 2021-03-02 (Crawled : 12:00) - globenewswire.com
GTHX | $3.99 -4.77% -5.28% 340K
|
Health Technology
|
| O: -0.3%
H: 2.17%
C: 1.7%
fda therapy commercialization fda approval trilaciclib
Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
Published: 2021-03-02 (Crawled : 11:03) - globenewswire.com
OYST | $11.17 0.18% -0.27%
|
Health Technology
|
| O: 3.7%
H: 3.24%
C: -0.76%
new drug disease nasal spray treatment fda fda acceptance eye eye disease drug
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
Published: 2021-03-02 (Crawled : 07:03) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 190K
|
Health Technology
|
| O: -3.18%
H: 2.21%
C: 1.76%
treatment fda fda acceptance
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.